Tải xuống
Tóm tắt
Brain metastases is common in patients with non-small cell lung cancer (NSCLC) and it is associated with poorer prognosis. Several options to control the secondary brain tumors in the context include chemotherapy, whole-brain radiation, stereotactic surgery, surgery. However, chemotherapy is ineffective to those patients because of poor penetration through the blood-brain barrier. Whole-brain radiation therapy used to be a standard option for brain metastases. However, it potentially damages normal brain tissues and causes neurocognitive decline. Stereotactic radiotherapy has been considered in cases of three or fewer lesions, and the lesions less than 3 cm. In selective cases, surgical removal of brain metastases can be done. These local therapies were accompanied by systemic treatment due to spreading of the cancer. Recently, molecular targeted therapy has opened up a new era in cancer treatment, especially NSCLC with brain metastases. In this review, we discuss brain metastases occurring in NSCLC patients with driver gene mutations with some briefly demonstrated cases.
Tài liệu tham khảo
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, 2018, doi: 10.3322/caac.21492.
S. R. Desai, “Lung cancer,” Lung Cancer, pp. 1–169, 2006, doi: 10.1017/CBO9780511545351.
A. Zabel and J. urgen Debus, “Trends in Diagnosis and Treatment of Lung Cancer,” Lung cancer, vol. 2, pp. S247–S252, 2004, doi: 10.1016/j.lungcan.2004.07.000.
D. Y. Shin, I. Il Na, C. H. Kim, S. Park, H. Baek, and S. H. Yang, “EGFR mutation and brain metastasis in pulmonary adenocarcinomas,” J. Thorac. Oncol., vol. 9, no. 2, pp. 195–199, 2014, doi: 10.1097/JTO.0000000000000069.
K. L. Johung et al., “Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis,” J. Clin. Oncol., vol. 34, no. 2, pp. 123–129, 2016, doi: 10.1200/JCO.2015.62.0138.
I. Zhang, N. G. Zaorsky, J. D. Palmer, R. Mehra, and B. Lu, “Targeting brain metastases in ALK-rearranged non-small-cell lung cancer,” Lancet Oncol., vol. 16, no. 13, pp. e510–e521, 2015, doi: 10.1016/S1470-2045(15)00013-3.
C. D’antonio et al., “Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies,” Ther. Adv. Med. Oncol., vol. 6, no. 3, pp. 101–114, 2014, doi: 10.1177/1758834014521110.
M. J. Edelman et al., “Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced NSCLC,” J. Thorac. Oncol., vol. 5, no. 1, pp. 110–116, 2010, doi: 10.1097/JTO.0b013e3181c59a3a.
I. Dagogo-Jack, C. M. Gill, D. P. Cahill, S. Santagata, and P. K. Brastianos, “Treatment of brain metastases in the modern genomic era,” Pharmacol. Ther., vol. 170, pp. 64–72, 2017, doi: 10.1016/j.pharmthera.2016.10.011.
D. Khuntia, P. Brown, J. Li, and M. P. Mehta, “Whole-brain radiotherapy in the management of brain metastasis,” J. Clin. Oncol., vol. 24, no. 8, pp. 1295–1304, 2006, doi: 10.1200/JCO.2005.04.6185.
S. Zimm, G. L. Wampler, D. Stablein, T. Hazra, and H. F. Young, “Intracerebral metastases in solid‐tumor patients: Natural history and results of treatment,” Cancer, vol. 48, no. 2, pp. 384–394, 1981, doi:10.1002/1097-0 1 4 2 ( 1 9 8 1 0 7 1 5 ) 4 8 : 2 < 3 8 4 : : A I D - CNCR2820480227>3.0.CO;2-8.
N. B. Ruderman and T. C. Hall, “Use of glucocorticoids in the palliative treatment of metastatic brain tumors,” Cancer, vol. 18, no. 3, pp. 298–306, 1965, doi: 10.1002/1097-0142(196503)18:3<298::AIDCNCR2820180306> 3.0.CO;2-H.
Y. Nakasu and K. I. Mitsuya, “Multidisciplinary management of brain metastases,” Japanese J. Cancer Chemother., vol. 37, no. 2, pp. 204–210, 2010, doi: 10.1634/theoncologist.12-7-884.
C. J. Langer and M. P. Mehta, “Current management of brain metastases, with a focus on systemic options,” J. Clin. Oncol., vol. 23, no. 25, pp. 6207–6219, 2005, doi: 10.1200/JCO.2005.03.145.
Y. Fan et al., “Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: Survival analysis in 210 patients,” Onco. Targets. Ther., vol. 6, pp. 1789–1803, 2013, doi: 10.2147/OTT.S52172.
Y. T. Lee, Y. J. Tan, and C. E. Oon, “Molecular targeted therapy: Treating cancer with specificity,” Eur. J. Pharmacol., vol. 834, pp. 188–196, 2018, doi: 10.1016/j.ejphar.2018.07.034.
Y. L. Wu et al., “CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: Data from a randomized Phase III trial (Aura3),” J. Clin. Oncol., vol. 36, no. 26, pp. 2702–2709, 2018, doi: 10.1200/JCO.2018.77.9363.
J. R. E. Choo, C. S. Tan, and R. A. Soo, “Treatment of EGFR T790M-Positive NSCLC,” Target. Oncol., vol. 13, no. 2, pp. 141–156, 2018, doi: 10.1007/s11523-018-0554-5.
S. M. Ben Abdallah and A. Wong, “Brain metastases in non-small-cell lung cancer: Are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?,” Curr. Oncol., vol. 25, no. June, pp. S103–S114, 2018, doi: 10.3747/co.25.3733.
E. Gourd, “Alectinib shows CNS efficacy in ALK-positive NSCLC,” Lancet. Oncol., vol. 19, no. 10, p. e520, 2018, doi: 10.1016/S1470-2045(18)30707-1.
| Đã xuất bản | 05-01-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 64 (2020) | |
| Phân mục | Báo cáo trường hợp | |
| DOI | 10.38103/jcmhch.2020.64.12 | |
| Từ khóa |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2020 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế